Evaluating Anti-Sickling Therapies for Sickle Cell Disease: A Microfluidic Assay for Red Blood Cell-Mediated Microvascular Occlusion under Hypoxia
Scholarly Commons @ Case Western Reserve University case.edu
Listen to this summary
Sickle cell disease (SCD) is characterized by the polymerization of hemoglobin S (HbS) upon deoxygenation, leading to the formation of sickled red blood cells (RBCs) with reduced deformability. Under hypoxic conditions, the impaired RBC behavior significantly contributes to vaso-occlusive events, hemolysis, and end-organ damage. Consequently, RBC deformability serves as a pivotal hemorheological biomarker for evaluating disease severity and therapeutic response. The OcclusionChip, a microfluidic assay, measures RBCs deformability through microcapillary occlusion. However, its current hypoxic assay relies on a complex nitrogen gas setup, rendering it bulky, expensive, and unsuitable for…
More ways to use this
Open on another device
Scan to open this page. Your saved notes and account access are not included.
U.S. urges critical infrastructure orgs to secure refrigeration systems ASAP after EU supermarket and blood bank attacks